NASDAQ:XERS Xeris Biopharma (XERS) Stock Forecast, Price & News $1.80 -0.05 (-2.70%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$1.78▼$1.8850-Day Range$1.80▼$2.6952-Week Range$0.97▼$3.07Volume1.13 million shsAverage Volume910,749 shsMarket Capitalization$248.52 millionP/E RatioN/ADividend YieldN/APrice Target$4.88 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Xeris Biopharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside170.8% Upside$4.88 Price TargetShort InterestHealthy5.37% of Shares Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$23,800 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.45) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector283rd out of 963 stocksPharmaceutical Preparations Industry118th out of 455 stocks 3.5 Analyst's Opinion Consensus RatingXeris Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.88, Xeris Biopharma has a forecasted upside of 170.8% from its current price of $1.80.Amount of Analyst CoverageXeris Biopharma has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.37% of the outstanding shares of Xeris Biopharma have been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Xeris Biopharma has recently decreased by 12.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXeris Biopharma has received a 62.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pancreatic hormones (H04)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Xeris Biopharma is -1.57. Previous Next 1.6 News and Social Media Coverage News SentimentXeris Biopharma has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Xeris Biopharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for XERS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows4 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.36% of the stock of Xeris Biopharma is held by insiders.Percentage Held by Institutions40.51% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xeris Biopharma are expected to grow in the coming year, from ($0.45) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXeris Biopharma has a P/B Ratio of 5.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xeris Biopharma (NASDAQ:XERS) StockXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.Read More XERS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XERS Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comIronwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains?September 14, 2023 | msn.comXeris Biopharma Holdings: On Track To Be Cash Flow PositiveSeptember 24, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 14, 2023 | finance.yahoo.comXeris to Participate in the 2023 Cantor Global Healthcare ConferenceAugust 29, 2023 | msn.comCraig-Hallum Initiates Coverage of Xeris Biopharma Holdings (XERS) with Buy RecommendationAugust 28, 2023 | finance.yahoo.comXeris to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 17, 2023 | finance.yahoo.comWhy I Bought Google Stock TodayAugust 11, 2023 | finance.yahoo.com10 Best Fast Growing Penny Stocks to Buy NowSeptember 24, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 10, 2023 | finance.yahoo.comXeris Biopharma CEO unveils record quarterly revenue, underpinned by unique business modelAugust 9, 2023 | proactiveinvestors.comXeris Biopharma CEO unveils record quarterly revenue growth,...Xeris Biopharma CEO unveils record quarterly revenue growth,...August 9, 2023 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)August 8, 2023 | finance.yahoo.comI Like This Small-Cap Stock Long-Term: This Is How I'll Trade ItAugust 8, 2023 | benzinga.comEarnings Outlook For Xeris Biopharma HoldingsAugust 8, 2023 | finance.yahoo.comXeris Biopharma Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | finance.yahoo.comStonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector DeclineAugust 1, 2023 | finance.yahoo.comXeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023July 31, 2023 | proactiveinvestors.comXeris Biopharma achieves shipping milestone for hypoglycemia treatment GvokeJuly 31, 2023 | finance.yahoo.comXeris Ships One Millionth Gvoke® UnitJune 29, 2023 | finance.yahoo.comXeris Biopharma CEO reveals impact of CSO's departure and exciting future plansJune 21, 2023 | proactiveinvestors.comXeris Biopharma says first participant dosed in Phase 2 clinical study of investigational subcutaneous levothyroxine in patients with hypothyroidismJune 21, 2023 | finance.yahoo.comXeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With HypothyroidismJune 17, 2023 | msn.comXeris Biopharma: Remarkable Market Share ExpansionJune 1, 2023 | finance.yahoo.comXeris Biopharma to Participate at the Jefferies Healthcare ConferenceMay 11, 2023 | msn.comHC Wainwright & Co. Reiterates Xeris Biopharma Holdings (XERS) Buy RecommendationMay 11, 2023 | markets.businessinsider.comXeris Pharmaceuticals (XERS) Gets a Buy from H.C. WainwrightMay 9, 2023 | finance.yahoo.comQ1 2023 Xeris Biopharma Holdings Inc Earnings CallSee More Headlines Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address XERS Company Calendar Last Earnings8/08/2023Today9/24/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XERS CUSIPN/A CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees355Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.88 High Stock Price Forecast$6.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+170.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,660,000.00 Net Margins-53.28% Pretax Margin-54.29% Return on Equity-191.02% Return on Assets-21.18% Debt Debt-to-Equity Ratio13.80 Current Ratio1.95 Quick Ratio1.50 Sales & Book Value Annual Sales$134.07 million Price / Sales1.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book5.45Miscellaneous Outstanding Shares138,066,000Free Float132,046,000Market Cap$248.52 million OptionableNot Optionable Beta1.72 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Paul R. Edick (Age 67)Chairman & CEO Comp: $1.12MMr. John P. Shannon (Age 61)Pres & COO Comp: $827.72kMs. Beth P. Hecht J.D. (Age 59)Chief Legal Officer & Corp. Sec. Comp: $638.31kMr. Steven M. Pieper (Age 46)Chief Financial Officer Ms. Allison WeySr. VP of Investor Relations & Corp. CommunicationsDr. Kenneth E. Johnson Pharm. D. (Age 60)Pharm.D., Sr. VP of Global Devel. & Medical Affairs Mr. Kevin McCullochChief Commercial OfficerMore ExecutivesKey CompetitorsOvid TherapeuticsNASDAQ:OVIDAtea PharmaceuticalsNASDAQ:AVIREnanta PharmaceuticalsNASDAQ:ENTAOcular TherapeutixNASDAQ:OCULFulcrum TherapeuticsNASDAQ:FULCView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemSold 4,962 shares on 8/21/2023Ownership: 0.032%Osaic Holdings Inc.Bought 5,500 shares on 8/21/2023Ownership: 0.012%Alliancebernstein L.P.Bought 31,050 shares on 8/15/2023Ownership: 0.051%Wells Fargo & Company MNBought 29,952 shares on 8/15/2023Ownership: 0.048%Citadel Advisors LLCBought 18,900 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions XERS Stock - Frequently Asked Questions Should I buy or sell Xeris Biopharma stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XERS shares. View XERS analyst ratings or view top-rated stocks. What is Xeris Biopharma's stock price forecast for 2023? 4 Wall Street research analysts have issued twelve-month target prices for Xeris Biopharma's shares. Their XERS share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $4.88 in the next twelve months. This suggests a possible upside of 170.8% from the stock's current price. View analysts price targets for XERS or view top-rated stocks among Wall Street analysts. How have XERS shares performed in 2023? Xeris Biopharma's stock was trading at $1.33 at the beginning of 2023. Since then, XERS stock has increased by 35.3% and is now trading at $1.80. View the best growth stocks for 2023 here. When is Xeris Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our XERS earnings forecast. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) issued its earnings results on Tuesday, August, 8th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The firm earned $38.01 million during the quarter, compared to analysts' expectations of $34.84 million. Xeris Biopharma had a negative trailing twelve-month return on equity of 191.02% and a negative net margin of 53.28%. What ETF holds Xeris Biopharma's stock ? iShares Neuroscience and Healthcare ETF holds 15,969 shares of XERS stock, representing 0.79% of its portfolio. What guidance has Xeris Biopharma issued on next quarter's earnings? Xeris Biopharma updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $145.00 million-$165.00 million, compared to the consensus revenue estimate of $149.35 million. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI). When did Xeris Biopharma IPO? (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager. What is Xeris Biopharma's stock symbol? Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS." Who are Xeris Biopharma's major shareholders? Xeris Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.89%), Caxton Corp (4.09%), Stonepine Capital Management LLC (3.98%), Geode Capital Management LLC (1.98%), State Street Corp (1.84%) and Northern Trust Corp (0.85%). Insiders that own company stock include Paul R Edick and Steven Prestrelski. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xeris Biopharma's stock price today? One share of XERS stock can currently be purchased for approximately $1.80. How much money does Xeris Biopharma make? Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $248.52 million and generates $134.07 million in revenue each year. The company earns $-94,660,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. How many employees does Xeris Biopharma have? The company employs 355 workers across the globe. How can I contact Xeris Biopharma? Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for the company is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com. This page (NASDAQ:XERS) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.